As reported in the Washington Post in July 2015, this was the only commercially available antivenin in the United States for the treatment of venomous snakebites until the release of a competing product, Anavip.

[5] Crotalid snakebites can range from mild to life-threatening, depending on the size and type of snake, the amount of venom injected and the location of the bite.

The most common adverse events reported in clinical studies were mild or moderate reactions involving the skin and appendages (primarily urticaria, rash, or pruritus), in 14 out of 42 patients.

Patients with allergies to papain, chymopapain, other papaya extracts or the pineapple enzyme bromelain may also be at risk for an allergic reaction to CroFab.

[6] Leslie Boyer, director of the VIPER Institute and a member of the team that developed CroFab, collected data on the cost of production and marketing, and found that the largest true cost to payers in the United States was that of the legal, regulatory and hospital activities involved in selling the drug, nearly 75% of the total.